PLYX logo

POLARYX THERAPEUTICS INC

PLYXNASDAQ
🏆 #4083 by market capUS Equity
$2.07▲ $0.03 (+1.47%)
🌅 Pre-market$2.05▼ 0.97%Regular close · extended-hours price shown
🔔
Track PLYX
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 1.5%
7d▼ 3.9%
14d▲ 2.0%
30d▲ 2.2%
ytd—
1y—
🏦Market Cap
$103M
Small Cap
📈Revenue Growth (YoY)
+0.0%
Slowing
📊Gross Margin
0.0%
Thin
💵FCF Margin
0.0%
Thin
⚖️P/S Ratio
0.0x
Cheap
Otter Score
60
Fair

Trading Snapshot

Day Range
$2.06 – $2.10
52-Week Range
$1.85 – $48.91
Volume
$2.12B
Avg Volume
$1.44B
Shares Outstanding
49.8M
Next Earnings
Dec 10, 2026

Fundamentals Snapshot

Annual Revenue
$11M
Last Q Revenue
$3M
P/E Ratio
-16.8
P/S Ratio
0.0x
EPS (TTM)
$-0.14
Dividend Yield
0.00%
Dilution (1yr)
−75.0%

Why Investors Own PLYX

  • ✓High-growth profile — revenue up -2.1% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 46% gross margin and 5% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

PLYX logo

POLARYX THERAPEUTICS INC

PLYX
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$8M▲ +79.7% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$4M▲ +53.3% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
47.3M▼ −75.0% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$5M▲ +$522K YoY
StockOtter · stockotter.space

About POLARYX THERAPEUTICS INC

Polaryx Therapeutics, Inc. functions as a biotechnology firm dedicated to advancing small-molecule therapies for lysosomal storage and neurodegenerative conditions. Its developmental pipeline includes a trio of promising candidates: PLX-100, which combines PLX-200 with an ancillary supplement, targeting late infantile neuronal ceroid lipofuscinosis (LINCL) and related forms of NCL. PLX-200, a repurposed compound already utilized to address various diseases in both adult and pediatric populations. And PLX-300, derived from an edible plant, which works by activating PPARa to enhance the production of transcription factor EB. The company, established in 2014, maintains its base of operations in Paramus, New Jersey.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
60/100

Analyst Ratings

ⓘ
Consensus
Buy
10 analysts
Strong Buy3
Buy6
Hold1
Sell0
Strong Sell0
Ratings as of Sep 2026

Latest News & Updates

GlobeNewsWire·29d ago

Polaryx Therapeutics Appoints Dr. Will Charlton as Chief Medical Officer

Dr. Charlton brings over 15 years of rare disease and pediatric drug development experience including CMO and clinical development roles

GlobeNewsWire·Aug 25

Polaryx Therapeutics Advances Operational Readiness for SOTERIA Phase 2 Basket Trial

Company on track to initiate SOTERIA trial in the second half of 2026 Clinical development activities advancing following FDA authorization, CRO engagement and Fast Track Designation across all four planned indication PA